Abstract: A medium supplement for high-yield culture of anaerobes is disclosed. The medium supplement includes N-acetylhexosamine, L-aspartic acid, L-cysteine and cobalamin. A culture medium including the supplement and a culture method using the culture medium are also disclosed. It is possible to provide an innovative method which is capable of achieving high-concentration culture of anaerobes that are difficult to culture in high yield. The method is cost-effective, and in particular, is capable of culturing large amounts of fastidious aerobes suitable for use in food and pharmaceutical applications.

Abstract: The present invention relates to a medium composition for culturing Faecalibacterium prausnitzii composed of vegetable peptone, yeast extract, a phosphate compound, a carbonate compound, cyanocobalamin (B12), L-cysteine, ammonium acetate, and maltose, and a method of mass-culturing Faecalibacterium prausnitzii using the medium composition. When the medium composition and the method for culturing Faecalibacterium prausnitzii according to the present invention are used, high-density culture and mass production of strains of Faecalibacterium prausnitzii phylogroup II are possible. In addition, when Faecalibacterium prausnitzii is mass-cultured in the medium composition free of animal components, it may be cultured at high density even in high-concentration anaerobic nitrogen gas, and thus it is possible to provide a culture method which is more economical and suitable for industrialization.

Abstract: Compositions containing extracellular vesicles (EVs) derived from a Faecalibacterium sp. strain are disclosed. The compositions can be used to prevent and/or treat cancer and/or ameliorate symptoms of cancer, and can be pharmaceutical composition, food stuffs, or dietary supplements. The compositions may contain a pharmaceutically acceptable carrier or excipient. The compositions exhibit an excellent effect on the prevention or treatment of cancer, or ameliorating symptoms of cancer.

Abstract: A novel Akkermansia muciniphila EB-AMDK39 strain (KCTC 13765BP) and composition containing the novel strain or extracellular vesicles (EVs) derived from the strain are disclosed. The composition can be in a form of pharmaceutical, food, or veterinary composition. The compositions are useful to preventing or treating cancer or inflammatory disease, or ameliorating cancer or inflammatory disease.

Abstract: A novel Akkermansia muciniphila strain is disclosed. The novel strain has effects of preventing or treating inflammatory or metabolic diseases. A composition containing the novel strain or a culture thereof are also disclosed. The novel strain, cultures thereof, or compositions containing the novel strain and/or cultures thereof are suitable to use in methods of preventing or treating inflammatory or metabolic diseases.

Abstract: A pharmaceutical composition effective for the prevention or treatment of atopic disease is disclosed. The pharmaceutical composition contains a Faecalibacterium prausnitzii EB-FPDK11 strain or a culture or dried product thereof. While traditional probiotics generally have an insignificant therapeutic effect for atopic disease, the pharmaceutical composition of the present invention exhibits a preventive or therapeutic effect on atopic disease at the same level as that of steroid-based drugs, and thus is not only promising as pharmabiotics, but also useful in the development of food and cosmetics.

Abstract: The present disclosure relates to a novel Faecalibacterium prausnitzii EB-FPDK9 strain and the use thereof. Administration of a composition containing at least one selected from the group consisting of the F. prausnitzii EB-FPDK9 strain, a culture of the strain, a lysate of the strain, and an extract of the strain has the effects of preventing, ameliorating and treating inflammatory disease, liver disease or metabolic disease.

Abstract: A pharmaceutical composition containing an Akkermansia muciniphila EB-AMDK19 strain or a culture or dried product thereof and uses thereof are disclosed. The composition is effective for the prevention or treatment of atopic disease. The pharmaceutical composition exhibits a preventive or therapeutic effect on atopic disease at the same level as that of steroid-based drugs, and thus is not only promising as pharmabiotics, but also useful in the development of food and cosmetics.

Abstract: A medium supplement for high-yield culture of anaerobes is disclosed. The medium supplement includes N-acetylhexosamine, L-aspartic acid, L-cysteine and cobalamin. A culture medium including the supplement and a culture method using the culture medium are also disclosed. It is possible to provide an innovative method which is capable of achieving high-concentration culture of anaerobes that are difficult to culture in high yield. The method is cost-effective, and in particular, is capable of culturing large amounts of fastidious aerobes suitable for use in food and pharmaceutical applications.

Abstract: The present disclosure relates to a novel Faecalibacterium prausnitzii EB-FETKil strain and the use thereof, Administration of a composition containing at least one selected from the group consisting of the F. prausnitzii EB-FOD11 strain, a culture of the strain, a lysate of the strain, and an extract of the strain has the effects of preventing, ameliorating and treating inflammatory disease, liver disease or metabolic disease.

Abstract: Disclosed are a novel Akkermansia muciniphila EB-AMDK27 strain having the effect of preventing or treating inflammatory disease or metabolic disease, and a pharmaceutical composition effective for preventing or treating inflammatory disease or metabolic disease, which contains the strain, a culture thereof, or a dried product thereof. While traditional probiotics generally have insufficient therapeutic effects on inflammatory or metabolic diseases, the disclosed next generation probiotic strain has an excellent effect on the prevention or treatment of inflammatory disease and/or metabolic disease so that it may be used as a new prophylactic and therapeutic tool.

Abstract: A medium supplement for high-yield culture of anaerobes is disclosed. The medium supplement includes N-acetylhexosamine, L-aspartic acid, L-cysteine and cobalamin. A culture medium including the supplement and a culture method using the culture medium are also disclosed. It is possible to provide an innovative method which is capable of achieving high-concentration culture of anaerobes that are difficult to culture in high yield. The method is cost-effective, and in particular, is capable of culturing large amounts of fastidious aerobes suitable for use in food and pharmaceutical applications.

Abstract: A medium supplement for high-yield culture of anaerobes is disclosed. The medium supplement includes N-acetylhexosamine, L-aspartic acid, L-cysteine and cobalamin. A culture medium including the supplement and a culture method using the culture medium are also disclosed. It is possible to provide an innovative method which is capable of achieving high-concentration culture of anaerobes that are difficult to culture in high yield. The method is cost-effective, and in particular, is capable of culturing large amounts of fastidious aerobes suitable for use in food and pharmaceutical applications.

Abstract: Disclosed are a novel Akkermansia muciniphila EB-AMDK27 strain having the effect of preventing or treating inflammatory disease or metabolic disease, and a pharmaceutical composition effective for preventing or treating inflammatory disease or metabolic disease, which contains the strain, a culture thereof, or a dried product thereof. While traditional probiotics generally have insufficient therapeutic effects on inflammatory or metabolic diseases, the disclosed next generation probiotic strain has an excellent effect on the prevention or treatment of inflammatory disease and/or metabolic disease so that it may be used as a new prophylactic and therapeutic tool.

Abstract: Disclosed are a novel Akkermansia muciniphila strain having the effect of preventing or treating inflammatory disease or metabolic disease, and a pharmaceutical composition effective for preventing or treating inflammatory disease or metabolic disease, which contains the strain or a culture thereof. While traditional probiotics generally have insufficient therapeutic effects on inflammatory or metabolic diseases, the disclosed next-generation probiotic strain has an excellent effect on the prevention or treatment of inflammatory disease and/or metabolic disease so that it may be used as a new prophylactic and therapeutic tool.